Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

Giannì, L.; Cole, Bernard F.; Panzini, Ilaria; Snyder, Raymond; Holmberg, Stig B.; Byrne, Michael; Crivellari, Diana; Colleoni, Marco; Aebi, Stefan; Simoncini, Edda; Pagani, Olivia; Castiglione‐Gertsch, Monica; Price, Karen N.; Goldhirsch, Aron; Coates, Alan S.; Ravaioli, Alberto

doi:10.1007/s00520-007-0295-y

Cited by 14 publications

(6 citation statements)

References 25 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low hemoglobin levels are often associated with a type of radical mastectomy surgery where Hb levels are lower than breast conservation surgery due to blood loss during surgery as described by Denison [15]. In this study, unrelated BMI related to anemia predictive factor is supported by research that explains that bone marrow atrophy occurs in some elderly people [16][17][18][19].…”

Section: Discussionsupporting

confidence: 61%

Incidence and Risk Factors of Anemia in Breast Cancer Patients having Chemotherapy in Dr. Moewardi Hospital

Ekorinawati¹,

Mudigdo²,

Wasita³

2019

Proceedings of the 3rd International Conference on Sport Science, Health, and Physical Education (ICSSHPE 2018)

View full text Add to dashboard Cite

The prevalence of breast cancer at Dr. Moewardi Hospital is currently ranked first on oncology cases at 18.92%. Chemotherapy is effective in fighting cancer cells, reducing tumor size, and giving a good prognosis in patients. Side effects of chemotherapy are indigestion with a manifestation of decreased food intake which has an impact on nutritional status and hemoglobin levels. Risk factors causing anemia are chemotherapy cycle, body mass index (BMI), age and initial hemoglobin. Objective: To determine the predictive factors of anemia caused by chemotherapy. Method: observational with cross sectional design. Subjects of the study were 115 patients aged 30-60 years who were taken randomly. Multivariate analysis with logistic regression to find the basic risk factors for anemia. Results: Anemia prevalence was 87%. The occurrence of anemia was significantly associated with four risk factors: Chemotherapy cycle (OR=0.282; 95% CI=0.078-1.015;p=0.053), BMI (OR = 7.544; 95% CI=0.962-59.174;p=0.054), Age (OR=0.925; 95% CI=0.396-2.180;p=0.865), Hb at baseline (OR=2.0; 95% CI=1.539-2.599;p=0.001). Conclusion: Identification of chemotherapy risk factors such as chemotherapy cycles, age, BMI, and Hb levels are important for patients at risk for anemia. These risk factors Hb at baseline are significantly associated with anemia in chemotherapy patients.

show abstract

Section: Discussionsupporting

confidence: 61%

Incidence and Risk Factors of Anemia in Breast Cancer Patients having Chemotherapy in Dr. Moewardi Hospital

Ekorinawati¹,

Mudigdo²,

Wasita³

2019

Proceedings of the 3rd International Conference on Sport Science, Health, and Physical Education (ICSSHPE 2018)

View full text Add to dashboard Cite

show abstract

“…3 Anemia is especially frequent in cancer patients treated with chemotherapy or radiotherapy. 4 Cancer-associated anemia can diminish the quality of life and limit the efficacy of anticancer therapy. 5 The anemia can be treated using erythropoiesis-stimulating agents, which modulate a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Treatment with Astragali Radix and Angelicae Radix Enhances Erythropoietin Gene Expression in the Cyclophosphamide-Induced Anemic Rat

Chang

Kim²,

Ko³

et al. 2009

Journal of Medicinal Food

View full text Add to dashboard Cite

Anemia is a common cause of morbidity and disease and reduces the quality of life. This study examined the effect of a combination treatment (AAC) using Astragali radix (AMW) and Angelicae radix (AGW) in cyclophosphamide (CYP)-induced anemic rats on erythropoietin (EPO) expression and hematological parameters. Male 4-week-old Sprague-Dawley rats were divided into five groups with or without CYP-induced anemia and individual or the combined herbal treatments according to the experimental protocol. After treatment, reverse transcription-polymerase chain reaction was used to evaluate the effects of AAC on erythropoietin expression, and blood and serological parameters were measured. The EPO mRNA levels were lower in the CYP-treated group, compared to the normal group, and higher in the AAC-treated group. In the CYP-treated group, the serum iron concentration, total iron-binding capacity, and vitamin B(12) level were lower, but these were normal or almost normal in the AAC-treated group. The CYP-treated group gained less weight than the normal group, but weight gain was partially normalized in the AAC group. The feed efficiency ratio was lowest in the CYP group, but the differences were not significant. The numbers of red blood cells, white blood cells, and platelets, the hematocrit, and the hemoglobin level were measured. The results revealed a reduced number of blood cells in the CYP-treated group, whereas the AAC-, AMW-, and AGW-treated groups showed significantly enhanced blood cell numbers compared to the CYP-treated control group and the AAC-treated group. AAC enhanced EPO mRNA expression in the CYP-induced anemic rat and improved the hematological parameters and vitamin B(12) status.

show abstract

“…Anemia is a blood disorder associated with a series of health problems, for example, chronic kidney disease, congestive heart failure, chronic renal failure, diabetic, and nondiabetic renal disease . In addition, the treatment of cancer in combining radiotherapy, chemotherapy, and noncardiac or nonvascular surgery could lead to anemia . Usually, blood transfusion is required for the anemic patients before therapy and surgery of these illnesses .…”

mentioning

confidence: 99%

A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide‐induced anemic rats

et al. 2017

View full text Add to dashboard Cite

By using a feedback system control scheme, the best combination of formononetin, ononin, calycosin, and calycosin‐7‐O‐β‐d‐glucoside derived from Astragali Radix was shown to activate a hypoxia response element, a regulator for erythropoietin (EPO) transcription, in kidney fibroblast. In cyclophosphamide‐induced anemic rats, the treatment of combined flavonoids, or EPO, improved the levels of red blood cells, white blood cells, hemoglobin, and hematocrit. In addition, the altered levels of antioxidant capacity, super oxidase dismutase, and malondialdehyde, triggered in anemic rats, were restored to control levels by the treatment of flavonoids. Here, we proposed a possible therapy by using the common flavonoids in treating anemia.

show abstract

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

Abstract: Moderate or severe anemia is rare among patients treated with AC followed by CMF. Low baseline hemoglobin and WBC are associated with a higher risk of anemia.

Cited by 14 publications

References 25 publications

Incidence and Risk Factors of Anemia in Breast Cancer Patients having Chemotherapy in Dr. Moewardi Hospital

Incidence and Risk Factors of Anemia in Breast Cancer Patients having Chemotherapy in Dr. Moewardi Hospital

Treatment with Astragali Radix and Angelicae Radix Enhances Erythropoietin Gene Expression in the Cyclophosphamide-Induced Anemic Rat

A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide‐induced anemic rats

Contact Info

Product

Resources

About